Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
RationaleOnly a small percentage of individuals seeking treatment for their marijuana use achieves sustained abstinence, suggesting more treatment options are needed.ObjectivesWe investigated the effects of baclofen (study 1) and mirtazapine (study 2) in a human laboratory model of marijuana intoxication, withdrawal, and relapse.MethodsIn study 1, daily marijuana smokers (n = 10), averaging 9.4 (±3.9) marijuana cigarettes/day, were maintained on placebo and each baclofen dose (60, 90 mg/day) for 16 days. In study 2, daily marijuana smokers (n = 11), averaging 11.9 (±5.3) marijuana cigarettes/day, were maintained on placebo and mirtazapine (30 mg/day) for 14 days each. Medication administration began outpatient prior to each 8-day inpatient phase. On the first inpatient day of each medication condition, participants smoked active marijuana (study 1: 3.3% THC; study 2: 6.2% THC). For the next 3 days, they could self-administer placebo marijuana (abstinence phase), followed by 4 days in which they could self-administer active marijuana (relapse phase); participants paid for self-administered marijuana using study earnings.ResultsIn study 1, during active marijuana smoking, baclofen dose-dependently decreased craving for tobacco and marijuana, but had little effect on mood during abstinence and did not decrease relapse. Baclofen also worsened cognitive performance regardless of marijuana condition. In study 2, mirtazapine improved sleep during abstinence, and robustly increased food intake, but had no effect on withdrawal symptoms and did not decrease marijuana relapse.ConclusionsOverall, this human laboratory study did not find evidence to suggest that either baclofen or mirtazapine showed promise for the potential treatment of marijuana dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of extended versus brief treatments for marijuana use.
Stephens, R. S., Roffman, R. A., & Curtin, L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.5.898 · Cited by 711
Cannabis use disorders in the USA: prevalence, correlates and co-morbidity
STINSON, F. S., RUAN, W. J., PICKERING, R., & GRANT, B. F. (2006) · Psychological Medicine · doi:10.1017/s0033291706008361 · Cited by 422 · cited 2×
“Self-administration In the United States, the number of individuals with disorders associated with marijuana use is twice that of any other illicit drug (SAMHSA 2007), with approximately 4 million adults meeting criteria for a lifetime diagnosis of marijuana dependence (Stinson et al. 2006).”
A randomized controlled trial of brief cognitive–behavioral interventions for cannabis use disorder
Copeland, J., Swift, W., Roffman, R., & Stephens, R. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00179-9 · Cited by 322 · cited 1×
“In fact, relapse rates for marijuana smokers are comparable to those found for other drugs of abuse (Copeland et al. 2001; Stephens et al. 1994, 2000; Moore and Budney 2003).”
Brief treatments for cannabis dependence: Findings from a randomized multisite trial
Babor, T. F., & The Marijuana Treatment Project Research Group (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.3.455 · Cited by 313
Budney, A. J., Moore, B. A., Rocha, H. L., & Higgins, S. T. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.4.2.307 · Cited by 290 · cited 1×
“The addition of contingency management procedures to motivational and cognitive therapy increased rates to over 27–37% at 1-year follow-up (Budney et al. 2006; Kadden et al. 2007), but there remains a clear need for improved treatment options for cannabis dependence.”
Controversies in translational research: drug self-administration.
Haney, M., & Spealman, R. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1079-x · Cited by 270 · cited 2×
“This laboratory model, which is designed to provide data on the interaction between medications and marijuana to guide treatment trials, is not attempting to mimic clinical conditions, but rather model behaviors in the laboratory that will be predictive clinically (see Haney and Spealman 2008 and Epstein et al. 2006 f…”
Self-citationDronabinol and Marijuana in HIV-Positive Marijuana Smokers: Caloric Intake, Mood, and Sleep
Haney, M., Gunderson, E. W., Rabkin, J., Hart, C. L., Vosburg, S. K., Comer, S. D., & Foltin, R. W. (2007) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31811ed205 · Cited by 184
Self-citationOral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms
Budney, A. J., Vandrey, R. G., Hughes, J. R., Moore, B. A., & Bahrenburg, B. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.014 · Cited by 180 · cited 2×
“Dronabinol (tetrahydrocannabidiol; Marinol) has been shown to significantly decrease many symptoms of withdrawal, including anxiety, trouble sleeping, chills, and marijuana craving under controlled conditions (Haney et al. 2004; Budney et al. 2007), but its effects on treatment outcome are not yet known.”
Abstinence rates following behavioral treatments for marijuana dependence
Kadden, R. M., Litt, M. D., Kabela-Cormier, E., & Petry, N. M. (2007) · Addictive Behaviors · doi:10.1016/j.addbeh.2006.08.009 · Cited by 173
Schmid, D. A., Wichniak, A., Uhr, M., Ising, M., Brunner, H., Held, K., Weikel, J. C., Sonntag, A., & Steiger, A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300923 · Cited by 165 · cited 1×
“We had hypothesized that mirtazapine’s sleep-enhancing effects, well documented in depressed patients (Schmid et al. 2006; Papakostas et al. 2008) and now demonstrated in marijuana-dependent volunteers, would decrease the amount of marijuana purchased after a bout of abstinence.”
Cited by
Angarita, G. A., Emadi, N., Hodges, S., & Morgan, P. T. (2016) · Addiction Science & Clinical Practice · doi:10.1186/s13722-016-0056-7 · Cited by 358
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“In a small human laboratory study of baclofen in cannabis intoxication, withdrawal and relapse (Haney et al., 2010), baclofen decreased craving for tobacco and cannabis in a dosedependent fashion, but had little effect on mood during abstinence and did not decrease relapse.”
BackgroundLevin, F. R., Mariani, J. J., Brooks, D. J., Pavlicova, M., Cheng, W., & Nunes, E. V. (2011) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.12.010 · Cited by 232
“…withdrawal symptoms (e.g. mitrazapine, nefazadone) whereas other medications have not shown any clear benefit in mitigating withdrawal symptoms (e.g., bupropion, divalproex) or in reducing the likelihood of relapse (e.g., baclofen) in the laboratory setting (Haney et al. 2001; 2003; 2004; 2010).”
BackgroundThe cannabis withdrawal syndrome: current insights
Bonnet, U., & Preuss, U. (2017) · Substance Abuse and Rehabilitation · doi:10.2147/sar.s109576 · Cited by 221
“Nevertheless, both the drugs had no effects on CWS in general or relapse prevention.(30,107) The withdrawal syndrome of SC receptor agonists(56) awaits further characterization and may respond to benzodiazepines and quetiapine.”
Treatment of Cannabis Use Disorder: Current Science and Future Outlook
Sherman, B. J., & McRae‐Clark, A. L. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1747 · Cited by 208
“Other Medication Classes The c-aminobutyric acid-B receptor agonist, baclofen, reduced cannabis craving during an active smoking paradigm but had limited impact on cannabis withdrawal symptoms in an inpatient laboratory evaluation.(50) Baclofen also did not decrease measures of cannabis relapse.”
Background
Metadata
- Authors
- Haney, M., Hart, C. L., Vosburg, S. K., Comer, S. D., Reed, S. C., Cooper, Z. D., & Foltin, R. W.
- Venue
- Psychopharmacology
- Published
- 2010-06-03
- Volume
- 211
- Issue
- 2
- Pages
- 233-244
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2094887764
- Cited by
- 78
- References
- 14
- FWCI
- 3.48
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. https://app.cochat.ai/papers/10.1007/s00213-010-1888-6
- The paper
- Haney, M., Hart, C. L., Vosburg, S. K., Comer, S. D., Reed, S. C., Cooper, Z. D., & Foltin, R. W. (2010). Effects of baclofen and mirtazapine on a laboratory model of marijuana withdrawal and relapse. Psychopharmacology. https://doi.org/10.1007/s00213-010-1888-6
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.